Three independent discounted-cash-flow-style models value SELLAS Life Sciences Group, Inc. Common Stock every trading day. 1 of 3 currently price SLS above its market price.
| Free Cash Flow model | $0.33 |
| Excess Profit model | $0.28 |
| Residual Earnings model | $14,716.43 |
| Dividend Discount model | — |
| Piotroski F-Score | 2 / 9 |
| Return on invested capital | -760.9% |
| Net debt / EBITDA | — |
| Gross margin | +90.0% |
| Revenue CAGR | -86.8% |
| Cash conversion | — |
| Dividend yield | — |
| Buyback yield | -25.3% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open SLS in StockKitty